{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:24:32Z","timestamp":1791321872742,"version":"4.3.1"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1607,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> S\u00e9ezary T cell\u2010activating factor (SAF) was originally defined as an inducer of functional interleukin\u20102 (IL\u20102) receptors on normal and malignant T cells in patients suffering from S\u00e9zary syndrome. In fact, a combination of SAF and IL\u20102 stimulated the propagation of T cell lines from the peripheral blood mononuclear cells (PBMC) of those patients, with approximately one third of those cell lines containing the predominant malignant clone as determined via cytogenetic and\/or T cell receptor gene rearrangement analysis. Although the primary source of SAF was mitogen\u2010stimulated PBMC of a patient with S\u00e9zary syndrome, we were unable to isolate the gene encoding SAF from eukaryotic libraries. However, we observed SAF activity in the cytoplasm of one of the malignant cell lines in a complex containing RNA and DNA. This observation led us to consider the possibility that SAF is not of eukaryotic origin. Intracellular pathogens replicate in the cytoplasm of host cells and contain proteins, DNA, and RNA. Using a panel of antichlamydial antibodies with confirmation from polymerase chain reaction primers, we found that most patients with mycosis fungoides were positive for these determinants. Immunoelectron microscopy and protein blotting further confirmed antibody reactivity. We showed that <jats:italic>Chlamydia pneumoniae<\/jats:italic> were capable of infecting normal human keratinocytes in culture. We also demonstrated that <jats:italic>C. pneumoniae<\/jats:italic> antigen expression was associated with active disease because these determinants were not expressed after psoralen and ultraviolet A therapy. We hypothesize that chronic infection by <jats:italic>C. pneumoniae<\/jats:italic> leads to expansion of <jats:italic>C. pneumoniae<\/jats:italic>\u2010specific T cells, thereby potentiating the development of cutaneous T cell lymphoma.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb03712.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T23:21:57Z","timestamp":1279668117000},"page":"69-85","source":"Crossref","is-referenced-by-count":46,"title":["Association between S\u00e9zary T Cell\u2010activating Factor, <i>Chlamydia pneumoniae<\/i>, and Cutaneous T Cell Lymphoma"],"prefix":"10.1111","volume":"941","author":[{"given":"J. TODD","family":"ABRAMS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRIAN J.","family":"BALIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ERIC C.","family":"VONDERHEID","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2000.0016"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/315602"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-10-199611150-00010"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12326693"},{"key":"e_1_2_11_6_2","first-page":"169","article-title":"Interferon\u2010inducible protein 10 as a possible factor in the pathogenesis of cutaneous T\u2010cell lymphomas","volume":"3","author":"Sarris A.H.","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30054-6"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12316249"},{"key":"e_1_2_11_9_2","first-page":"399","article-title":"Phase I trial of a ligand fusion\u2010protein (DAB389IL\u20132) in lymphomas expressing the receptor for interleukin\u20102","volume":"91","author":"LeMaistre C.F.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1994.tb01066.x"},{"key":"e_1_2_11_11_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.4049\/jimmunol.146.5.1455","article-title":"Malignant and nonmalignant T cell lines from human T cell lymphotropic virus type I\u2010negative patients with S\u00e9zary syndrome","volume":"146","author":"Abrams J.T.","year":"1991","journal-title":"J. Immunol."},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)00059-X"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1974.tb12449.x"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12514693"},{"key":"e_1_2_11_15_2","first-page":"5501","article-title":"S\u00e9zary T\u2010cell\u2010activating factor induces functional interleukin 2 receptors on T\u2010cells derived from patients with S\u00e9zary syndrome","volume":"53","author":"Abrams J.T.","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(86)90050-6"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/9.12.1857"},{"key":"e_1_2_11_18_2","first-page":"99","article-title":"A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens [published erratum appears in J","volume":"230","author":"Givan A.L.","year":"1999","journal-title":"Immunol. Methods 2000 Apr 3; 237(1\u20132): 207]. J. Immunol. Methods"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80386-U"},{"key":"e_1_2_11_20_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/CDLI.6.6.895-905.1999","article-title":"S\u00e9zary T\u2010cell activating factor is a Chlamydia pneumoniae\u2010associated protein","volume":"6","author":"Abrams J.T.","year":"1999","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2663.2663"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2000.tb00857.x"},{"key":"e_1_2_11_23_2","first-page":"160","article-title":"The role of human T\u2010cell lymphotropic viruses (HTLV\u2010I and II) in cutaneous T\u2010cell lymphomas","volume":"13","author":"Zucker\u2010Franklin D.","year":"1994","journal-title":"Semin. Dermatol."},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004300050071"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00003"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2000.41.3.319"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01294.x"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.22.2568"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.2000.0360"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199907)46:1<6::AID-ANA4>3.0.CO;2-M"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02786470"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.1997.d01-413.x"},{"key":"e_1_2_11_33_2","first-page":"18","article-title":"Cell mediated immunity to Chlamydia pneumoniae","volume":"104","author":"Halme S.","year":"1997","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.5522"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb03712.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb03712.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T15:29:45Z","timestamp":1695655785000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb03712.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb03712.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb03712.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}